{‘She has little qualifications’: the US healthcare establishment prepares for Høeg's role at the FDA.

Given that the United States proceeds with unprecedented revisions to its immunization guidelines, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning coronavirus shots during the global health crisis and has zeroed in on potential fatalities following Covid vaccination in her recent time at the FDA.

Scheduled Shifts to Childhood Immunization Program

Public health authorities were set to announce sweeping revisions to the pediatric immunization program in December, aligning the US with the Danish national calendar, it is understood – a substantial departure that would place the US out of step with a large portion of the world with insufficient data for benefit. The planned update has been postponed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for ending specific pediatric vaccine recommendations in the US to become more in line with Denmark, a society with nationalized medicine and a population about the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Background

The appointee has no obvious background in medication creation, oversight or administrative roles, which has been customary for previous leaders of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a large organization. She is not an expert in industry regulation.”

Previous directors of the center would “grasp regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who headed CBER have had.”

This division has an immense portfolio at the agency, she pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic program approves thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and every single one need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative component to the role, which oversees over 5,000 employees. “It’s a huge management job, if you execute it properly,” Woodcock added.

Official Statement and Contentious Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a press secretary responded that the “concerns are based on flawed assumptions”.

“Her resume is consistent with the functions of her job,” the official stated, noting the months Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched priority voucher program, a contentious expedited therapy clearance system that apparently worried her preceding directors. “How are these therapies being selected for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the agency appears to be shifting towards more relaxed oversight of pharmaceuticals, except for shots.”

Documented Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if problematic, history, critics have noted. She released a analysis using unverified crowd-sourced reports to estimate the incidence of myocarditis after COVID-19 vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new government included revising rules for novel immunizations and ending “non-essential” vaccines, she said following the vote on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of excluding teenage boys from receiving COVID-19 vaccinations.

“She is an thorough ideologue who begins with her beliefs and tailors the evidence to retrofit the science in a very disingenuous, untruthful manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|